Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
Fate Therapeutics, a clinical-stage biopharmaceutical company specializing in iPSC-derived cellular immunotherapies, will participate in five major healthcare investor conferences in Q2 2026. These events will provide updates and engagement opportunities with investors through presentations and webcast sessions.